Paul Little - Feb 1, 2023 Form 4 Insider Report for Eledon Pharmaceuticals, Inc. (ELDN)

Role
Chief Financial Officer
Signature
/s/ Paul Little
Stock symbol
ELDN
Transactions as of
Feb 1, 2023
Transactions value $
$0
Form type
4
Date filed
2/2/2023, 04:40 PM
Previous filing
Feb 2, 2022
Next filing
May 2, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELDN Stock Option (right to buy) Award $0 +155K $0.00 155K Feb 1, 2023 Common Stock 155K $3.08 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase up to 155,000 shares of Common Stock, which option vests with respect to 38,750 shares on February 1, 2024, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending February 1, 2027.